Suppression of NRF2 expression by VPA44–46 and other HDAC inhibitors47,48 were also seen in cancer and other disease and is proposed to be a plausible approach to enhance antitumor activity of TRAIL or EGFR inhibitors. This evidence concerns the gene HDAC9 and cancer.